Form 4 Filing for Evogene Ltd.

This filing details transactions made by Tarcic Gabi, Chief Development Officer of Evogene Ltd. On June 4, 2026, Tarcic Gabi acquired 1129 ordinary shares at a price of $0.6 per share. The filing also mentions stock options granted on November 20, 2024, with a vesting period of four years and an exercise price of $2.305. The total number of underlying ordinary shares for these options is 40000. The filing includes a Power of Attorney document, authorizing Nitsan Deutsch to execute and file necessary SEC forms on behalf of Tarcic Gabi. This Power of Attorney remains effective until Tarcic Gabi is no longer required to file, revokes it in writing, or Nitsan Deutsch is no longer employed by the company.